Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113384251> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2113384251 endingPage "957" @default.
- W2113384251 startingPage "955" @default.
- W2113384251 abstract "Hurvitz SA, Dirix L, Kocsis J et al. Phase II randomised study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31(9), 1157–1163 (2013). The introduction of trastuzumab in the treatment of HER-2-positive metastatic breast cancer patients favorably changed the natural history of this disease. First-line treatment with trastuzumab and taxanes demonstrated a significant improvement in overall survival and progression-free survival compared with taxane alone. Despite such a major advance, HER-2-positive metastatic breast cancer will eventually progress in most patients. Moreover chemotherapy-associated toxicities, such as myelosuppression (docetaxel) and neurotoxicity (paclitaxel), may hamper the possibility to adequately treat metastatic breast cancer and may have a negative effect on patients’ quality of life. The need for more effective and better-tolerated therapy for HER-2-positive metastatic breast cancer led to the development of new anti-HER-2 agents. Pertuzumab and trastuzumab emtansine are two of the new agents that will change the approach to the treatment of HER-2-positive metastatic breast cancer. Pertuzumab is a humanized monoclonal antibody that binds HER-2 at a different epitope of the HER-2 extracellular domain (subdomain II) than that at which trastuzumab binds. Trastuzumab emtansine is a HER-2-targeted antibody–drug conjugate, composed of the cytotoxic microtubule polymerization inhibitor DM1 that is conjugated to the monoclonal antibody trastuzumab, able to selectively deliver a cytotoxic agent to HER-2-positive tumor cells. TDM-1 is superior and less toxic than lapatinib plus capecitabine in metastatic breast cancer patients previously treated with trastuzumab and taxanes, and its role as a first-line therapy is currently under investigation." @default.
- W2113384251 created "2016-06-24" @default.
- W2113384251 creator A5020297889 @default.
- W2113384251 creator A5039478541 @default.
- W2113384251 creator A5074479074 @default.
- W2113384251 date "2013-07-01" @default.
- W2113384251 modified "2023-10-16" @default.
- W2113384251 title "Trastuzumab emtansine in the treatment of <i>HER-2</i>-positive metastatic breast cancer patients" @default.
- W2113384251 cites W1979570645 @default.
- W2113384251 cites W2127457632 @default.
- W2113384251 cites W2136527721 @default.
- W2113384251 cites W2159967578 @default.
- W2113384251 cites W2166199281 @default.
- W2113384251 doi "https://doi.org/10.2217/fon.13.74" @default.
- W2113384251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23837759" @default.
- W2113384251 hasPublicationYear "2013" @default.
- W2113384251 type Work @default.
- W2113384251 sameAs 2113384251 @default.
- W2113384251 citedByCount "9" @default.
- W2113384251 countsByYear W21133842512014 @default.
- W2113384251 countsByYear W21133842512015 @default.
- W2113384251 countsByYear W21133842512016 @default.
- W2113384251 countsByYear W21133842512019 @default.
- W2113384251 countsByYear W21133842512020 @default.
- W2113384251 crossrefType "journal-article" @default.
- W2113384251 hasAuthorship W2113384251A5020297889 @default.
- W2113384251 hasAuthorship W2113384251A5039478541 @default.
- W2113384251 hasAuthorship W2113384251A5074479074 @default.
- W2113384251 hasConcept C121608353 @default.
- W2113384251 hasConcept C126322002 @default.
- W2113384251 hasConcept C143998085 @default.
- W2113384251 hasConcept C2775930923 @default.
- W2113384251 hasConcept C2776387010 @default.
- W2113384251 hasConcept C2777292972 @default.
- W2113384251 hasConcept C2777329042 @default.
- W2113384251 hasConcept C2777511904 @default.
- W2113384251 hasConcept C2778087150 @default.
- W2113384251 hasConcept C2779786085 @default.
- W2113384251 hasConcept C2781164504 @default.
- W2113384251 hasConcept C2781190966 @default.
- W2113384251 hasConcept C530470458 @default.
- W2113384251 hasConcept C71924100 @default.
- W2113384251 hasConceptScore W2113384251C121608353 @default.
- W2113384251 hasConceptScore W2113384251C126322002 @default.
- W2113384251 hasConceptScore W2113384251C143998085 @default.
- W2113384251 hasConceptScore W2113384251C2775930923 @default.
- W2113384251 hasConceptScore W2113384251C2776387010 @default.
- W2113384251 hasConceptScore W2113384251C2777292972 @default.
- W2113384251 hasConceptScore W2113384251C2777329042 @default.
- W2113384251 hasConceptScore W2113384251C2777511904 @default.
- W2113384251 hasConceptScore W2113384251C2778087150 @default.
- W2113384251 hasConceptScore W2113384251C2779786085 @default.
- W2113384251 hasConceptScore W2113384251C2781164504 @default.
- W2113384251 hasConceptScore W2113384251C2781190966 @default.
- W2113384251 hasConceptScore W2113384251C530470458 @default.
- W2113384251 hasConceptScore W2113384251C71924100 @default.
- W2113384251 hasIssue "7" @default.
- W2113384251 hasLocation W21133842511 @default.
- W2113384251 hasLocation W21133842512 @default.
- W2113384251 hasOpenAccess W2113384251 @default.
- W2113384251 hasPrimaryLocation W21133842511 @default.
- W2113384251 hasRelatedWork W2085871826 @default.
- W2113384251 hasRelatedWork W2112335800 @default.
- W2113384251 hasRelatedWork W2113384251 @default.
- W2113384251 hasRelatedWork W2118302460 @default.
- W2113384251 hasRelatedWork W2561142218 @default.
- W2113384251 hasRelatedWork W2905960639 @default.
- W2113384251 hasRelatedWork W3088751691 @default.
- W2113384251 hasRelatedWork W3123611170 @default.
- W2113384251 hasRelatedWork W3174405896 @default.
- W2113384251 hasRelatedWork W4248292794 @default.
- W2113384251 hasVolume "9" @default.
- W2113384251 isParatext "false" @default.
- W2113384251 isRetracted "false" @default.
- W2113384251 magId "2113384251" @default.
- W2113384251 workType "article" @default.